by on 
Pharmacy Journal from Royal Pharmaceutical Society
#Glucagonlikepeptide1 #analoguesadults #type2 #diabetesmellitus
After reading this article, you must be able to: Understand the mechanism of analog action peptide-1 such as glucagon;
Understanding the place in GLP-1 analog therapy for glycemic control in type 2 diabetes mellitus;
Beware of Warnings, Contraindications, and Side Effects for Analog GLP-1.
Peptide-1 such as glucagon is the hormone intestinal incretin released from distal ileum and large intestine in response to food intake. GLP-1 plays an important role in glucose homeostasis, stimulates the release of insulin and inhibits glucagon release, produces a decrease in blood glucose. GLP-1 also has an extra pancreas effect, which includes slowing the emptying of the stomach and the central effect on the brain, which leads to a sense of fullness and reduced appetite [1]. Figures 1 and 2 show the normal function of GLP-1 in human health and mechanisms by giving this effect [2]. In people with type 2 diabetes mellitus, this secretion is disrupted, thus disrupting normal homeostasis and results in an increase in blood glucose levels [3]. This discovery has led to the development of analog GLP-1 for the treatment of T2DM.
Analog GLP-1 can be called GLP-1 or Mimetic Agonist GLP-1. GLP-1 agonists bind and activate GLP-1 receptors to increase insulin secretion, suppress glucagon secretion and slow gastric emptying [4].
Figure 1: Peptide effects such as glucagon in human physiology
Figure 2: The mechanism in which analog GLP-1 has a beneficial effect
This article describes the GLP-1 analog place in broader therapy, while also highlighting relevant warnings, contraindications and side effects, with the aim of supporting safe recipes and the use of GLP-1 analogs for glycemic control in adults with T2DM.
GLP-1 Analog Overview available
Analog GLP-1 is classified based on whether the backbone of the compound is human or inherited [5-11]. Exendin is a protein agonist Peptide-1 receptor which is usually found and produced in the reptile intestine that lives in the desert [12]. Analog GLP-1 is different in the duration of their actions, each half-life and administrative routes and therefore requires different administrative frequencies.
Table 1: Analog GLP-1
Who might benefit from GLP-1 therapy?
Like any pharmacological therapy, it is important that GLP-1 therapy is given to those who are most likely to benefit.
GLP-1 therapy must be considered in people with high risk indicators or established atheroscler